Evidence map›Paper›PMID 30871576›Full record

ArticleBMC medical genomics2019

Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines.

Sergey V Kulemzin, Daria A Matvienko, Artur H Sabirov, Arpine M Sokratyan, Daria S Chernikova, Tatyana N Belovezhets, Anton N Chikaev, Aleksandr V Taranin, Andrey A Gorchakov

Open access · goldAbstract read
In one paragraph

Article in BMC medical genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Engineered CD4 T cells for in vivo delivery of therapeutic proteins.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Medical genomics research at BGRS-2018.BMC medical genomics · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sergey V KulemzinInstitute of Molecular and Cellular Biology SB RAS, Novosibirsk, Russia.
Daria A MatvienkoInstitute of Molecular and Cellular Biology SB RAS, Novosibirsk, Russia.
Artur H SabirovInstitute of Molecular and Cellular Biology SB RAS, Novosibirsk, Russia.
Arpine M SokratyanInstitute of Molecular and Cellular Biology SB RAS, Novosibirsk, Russia.
Daria S ChernikovaInstitute of Molecular and Cellular Biology SB RAS, Novosibirsk, Russia.
Tatyana N BelovezhetsInstitute of Molecular and Cellular Biology SB RAS, Novosibirsk, Russia.
Anton N ChikaevInstitute of Molecular and Cellular Biology SB RAS, Novosibirsk, Russia.
Aleksandr V TaraninInstitute of Molecular and Cellular Biology SB RAS, Novosibirsk, Russia.
Andrey A GorchakovInstitute of Molecular and Cellular Biology SB RAS, Novosibirsk, Russia. gorchakov@mcb.nsc.ru.
Institute of Molecular and Cell Biology · RUNovosibirsk State University · RUSiberian Branch of the Russian Academy of Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCytotoxic activity of T- and NK-cells can be efficiently retargeted against cancer cells using chimeric antigen receptors (CARs) and rTCRs. In the context of solid cancers, use of armored CAR T- and NK cells secreting additional anti-cancer molecules such as cytokines, chemokines, antibodies, BiTEs, inverted cytokine receptors, and checkpoint inhibitors, appears particularly promising, as this may help overcome immunosuppressive tumor microenvironment, attract bystander immune cells, and boost CAR T/NK-cell persistence. Placing the expression of such molecules under the transcriptional control downstream of CAR-mediated T/NK-cell activation offers the advantage of targeted delivery, high local concentration, and reduced toxicity. Several canonic DNA sequences that are known to function as activation-inducible promoters in human T and B cells have been described to date and typically encompass the multimers of NFkB and NFAT binding sites. However, relatively little is known about the DNA sequences that may function as activation-driven switches in the context of NK cells. We set out to compare the functionality of several activation-inducible promoters in primary human T cells, as well as in NK cell lines NK-92 and YT.

methodsLentiviral constructs were engineered to express two fluorescent reporters: mCherry under 4xNFAT, 2xNFkB, 5xNFkB, 10xNFkB, 30xNFkB promoters, as well as two variants of the CD69 promoter, and copGFP under the strong constitutive promoter of the human EF1a gene. Pseudotyped lentiviral particles obtained using these constructs were transduced into primary human T cells and NK-92 and YT cell lines expressing a CAR specific for PSMA. The transgenic cells obtained were activated by CD3/CD28 beads (T cells) or via a CAR (CAR-NK cell lines). Promoter activity before and after activation was assayed using FACS analysis.

resultsIn T cells, the CD69 promoter encompassing CNS1 and CNS2 regions displayed the highest signal/noise ratio. Intriguingly, in the context of CAR-YT cell line neither of the seven promoters tested displayed acceptable activation profile. In CAR-NK-92 cells, the largest fold activation (which was modest) was achieved with the 10xNFkB and 30xNFkB promoters, however its expression was clearly leaky in "resting" non-activated cells.

conclusionsUnlike in T cells, the robust activation-driven inducible expression of genetic cassettes in NK cells requires unbiased genome-wide identification of promoter sequences.

Indexed as

Genes, ReporterAntigens, CDAntigens, Differentiation, T-LymphocyteCD69 AntigensCell LineGenetic VectorsHumansKiller Cells, NaturalLectins, C-TypeLentivirusNFATC Transcription FactorsNF-kappa BPromoter Regions, GeneticReceptors, Chimeric AntigenT-LymphocytesAntigens, CDAntigens, Differentiation, T-LymphocyteCD69 AntigensLectins, C-TypeNFATC Transcription FactorsNF-kappa BReceptors, Chimeric AntigenCancerChimeric antigen receptorInducible promoterNK cell linesReporter

Identifiers

PMID30871576
PMCPMC6417161
OpenAlexW2921016876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.